13	12	11	10	9	∞	7	ი	თ	4	ω	2	-		Ð
c.892C>T	c.2257C>T	c.1874G>C	c.1622C>A	c.1084C>T	c.901_903del	c.812G>A	c.801_803del	c.766C>G	c.753G>T	c.709-2A>G	c.685C>T	c.265del	change	mRNA
35062270 G>A	35057434 G>A	35059623 C>G	35060386 G>T	35061687 G>A	35062258 AGAT>A	35062350 C>T	35062985 CAAG>C	35063023 G>C	35063036 C>A	35063082 T>C	35064177 G>A	35067927 CG>C	(chr9)	Genomic location
p.Pro298Ser	p.Arg753Trp	p.Arg625Pro	p.Ser541Tyr	p.Arg362Cys	p.lle301del	p.Gly271Asp	p.Phe267del	p.Arg256Gly	p.Lys251Asn	Splice variant	p.Leu229Phe	p.Arg89Glyfs*8		Protein change
8/D1	16/D2	14/D2	14/D2	10/D1	8/D1	8/D1	7/D1	7/D1	7/D1	6-7/D1	6/D1	3/N	domain	Exon/
SUA	SUA	SUA	VUS	VUS	VUS	VUS	VUS	VUS	VUS	SUA	VUS	SUA	class	Lab
PM2	PM2	PM2	PM2	PM2	PM2	PM2	PM2	PM2	PM2	PM2	PM2	PM2	freq	Allel.
PS2	BS4	PS2	PM6	PS2	PS2	PS2	PS2	PM6	PS2	PS2	PS2*	PS2	-ance	Inherit
					PM4		PM4			PVS1-M		PVS1-M	on prot.	Effect
PP3	PP3-M	PP3-S	PP3-M	PP3-S		PP3-S		PP3-M	PP3-M		PP3		silico	In
0.71	0.90	0.96	0.86	0.98		0.96		0.89	0.84		0.73		score	REVEL
3.94/26.6	4.53/32	4.31/29.6	4.18/28.6	4.80/33		4.57/32		3.49/24.7	3.35/24.3	6.06/35	4.06/27.5		score	CADD
PP2	PP2	PP2	PP2	PP2		PP2		PP2	PP2		PP2		data	Funct.
LÞ	SNA	Path	LP	Path	P	LP	P	ĿP	LP	P	LP	LP	class	ACMG

Supplementary Table 1: VCP variant classification

mRNA change is based on transcript NM_007126.5; genomic location is based on GRCh38.p13 (v1.6, hg38). Classifications of variants in VCP scaled scores are compared to all other SNVs and scored by rank order of magnitude (5). population databases, inheritance mode/segregation with disease, in silico predicted effects on protein (based on REVEL score, but CADD use the reporting lab's classification (Lab class) as well as ACMG guidelines (ACMG class) to score pathogenicity based on allele frequency in 5). CADD score reflects likelihood variant is observed (negative) vs. not observed/only simulated (positive); raw scores are directly from model, raw/scaled scores also provided), functional data based on mechanism of disease and published data on similar variants in the gene of interest (1-

Key for the criteria used:

concerns in his 50s, but no report of developmental delay, so considered not affected (and therefore disease not segregating) Benign strong 4 (BS4): non-segregation with disease. Proband 12 had a paternally inherited variant; father with ADHD and possible memory

Pathogenic supporting 2 (PP2): missense variant in a gene with low ratio of benign to pathogenic missense variants Pathogenic supporting 3 (PP3): *In silico* predictions with REVEL score of 0.663-0.773; modified to PP3-M (moderate) with REVEL score of 0.773-0.932, and PP3-S (strong) with REVEL score of >0.932

Pathogenic moderate 2 (PM2): none of the variants was reported in gnomAD (last accessed Mar 2023)

Pathogenic moderate 4 (PM4): protein length-changing variant

Pathogenic moderate 5 (PM6): de novo without maternity/paternity confirmed (i.e., panel testing)

Pathogenic strong 2 (PS2): de novo with maternity/paternity confirmed (i.e., confirmed by trio exome analysis)

Variant of uncertain significance (VUS): insufficient evidence to label as likely pathogenic or benign is not proven mechanism of disease in humans but null mouse model is affected (embryonic lethal)(6), has been downgraded to moderate. Pathogenic very strong (PVS1): predicted null variant in a gene where loss of function is a known mechanism of disease; given haploinsufficiency

Pathogenic: two strong predictions, among other criteria found in (1) Likely pathogenic (LP): one strong and two moderate/supporting predictions, or ≥3 moderate predictions, among other criteria found in (1)

Proband 2/PS2: Half-brother also appears affected, but did not have genetic testing. Not present in parents, so scored as de novo here.

P#	Age (v)	Sex	Pregnancy/birth complications	Relevant family history	Other genetic/metabolic testing
1	0-5	Μ	Low amniotic fluid, brief NICU stay for hypothermia	Maternal half-brother w/suspected autism	Elevated vitamin B12. Normal: carnitine, acylcarnitines, AA, UOA, urine C5-DC, urine GAGs, TSH. Normal CK.
2	6-10	Σ	Pre-eclampsia, C/S at term	Half-brother with similar features, not tested.	<u>VUS in <i>TRPC5</i> (c.2332T>C, p.S778P), maternally inherited</u> . Normal: CMA, UOA, carnitine; Fragile-X testing with 23 repeats. Normal CK, ALP, EMG, muscle ultrasound.
ω	6-10	п	Fraternal twin (clomiphene), oligohydramnios, premature C/S, 3mo stay in NICU for poor feeding	Speech delay (both sides); twin with short stature and speech delay	Normal: CMA. ALP elevated to 436 (ref <317) during acute illness.
4	11-15	Ζ	None	5 healthy siblings, 1 intrauterine fetal demise	Normal: CMA, Fragile-X, ANG/PWS MLPA, <i>ZEB2</i> seq + MLPA, DDG2P panel. Normal CK, EMG. One normal, one ↑ ALP level. <u>NCV</u>
л	11 <u>-</u> 17	Z	None	No additional info	with demyelinating sensorimotor polyneuropathy.
о	0-5 0	т	C/S at term	No additional info	Normal: karyotype, aCGH. Normal CK and ALP.
7	0-5	F	Mild gDM, C/S at term	Father with small VSD	Normal: karyotype, aCGH, PWS, metabolic screening. Normal CK.
œ	11-15	Σ	Premature C/S for twin pregnancy, choroid plexus bleeding 2° hydronenbrosis	Noncontributory	Normal: karyotype, aCGH, SNRPN MLPA. Normal CK and ALP.
9	16-20	Z	Oligohydramnios, gDM requiring insulin, C/S at term for fetal decelerations	No additional info	Low carnitine with pathogenic variant in <i>SLC22A5</i> (p.P46S). Normal: karyotype, Fragile-X, subtelomere FISH, oligo microarray, mtDNA seq. Normal CK, ALP, NCV. EMG with sensorimotor polyneuropathy
10	11-15	п	AMA, term C/S for bradycardia	Noncontributory	
<u>+</u> -	21-25	п	↓ Fetal movement in 2T, oligohydramnios, vacuum- assisted delivery term, 10d NICU stay for UTI & poor feeding	No additional info	POA suggestive of succinic semialdehyde dehydrogenase deficiency. Normal: karyotype, <i>CPT-2</i> seq, Fragile-X, mtDNA panel, CSF, metabolic workup (see P11 supplement). <u>EMG with mixed</u> myopathy/neuropathy, normal 6 years later. Normal ALP.
12	16-20	Μ	C/S at term	Father with ADHD, memory concerns 50s.	Normal: CMA, metabolic workup (see Proband 10 supplement), mtDNA seq and deletion. Normal ALP.
13	11-15	Р	None	Noncontributory	Normal: CMA, sequencing of <i>SLC2A1</i> and <i>STXBP1</i> , chromosome 15 methylation studies. Normal CK and ALP.
Key:	b lement a Age = a(ary Tabl	Supplementary Table 2: Proband phenotypes (demographics and other contributing factors) Key: Age = age at last evaluation/clinical update. Sex: M = male, F = female. Ethnicity: NE = norther programmer // which complementary AMA = programmer and material and C/C = Constraint position and a female and	<pre>emographics and other c X: M = male, F = female. E Accord and C/C = Concert </pre>	Supplementary Table 2: Proband phenotypes (demographics and other contributing factors) Key: Age = age at last evaluation/clinical update. Sex: M = male, F = female. Ethnicity: NE = northern European, A = Asian (Thai), H = Hispanic.
inten	nancy/bir	unit, 21	The second trimester. Other tes	ting: AA = amino acids, at	Pregnancy/pirth complications: AMA = advanced matemal age, C/S = Caesarian section, gDM = gestational diabetes mellitus, NiCU = neonatal intensive care unit, 2T = second trimester. Other testing: AA = amino acids, aCGH = comparative genomic hybridization array, ALP = alkaline

phosphatase, ANG/PWS = Angelman syndrome/Prader-Willi syndrome, CMA = chromosomal microarray, CK = creatinine (phospho)kinase, CSF = cerebrospinal fluid, DDG2P = Developmental Disorders Genotype-to-Phenotype database (>1000 curated genes), EMG = electromyography, GAG = glucosaminoglycan, MLPA = Multiplex Ligation-dependent Probe Amplification, mtDNA = mitochondrial DNA, MPS = mucopolysaccharides, NCV = nerve conduction velocity, POA = plasma organic acids, UOA = urine organic acids, seq = sequencing, SNP =

single nucleotide polymorphism, TSH = thyroid stimulating hormone, UTI = urinary tract infection.

Total	13	12		11		10	9	8		7	თ		5		4		ι. C	,	2		-	Normal		P#
	+	+-		+		+	+	+		+	+		+		+		+		+		+/-	·		_
13/13			hemiparesis	Coordination c/b			Poor balance	Walks with orthosis	sit when placed but not independently. Cannot walk.	Can lift head. roll. and				uses wheelchair	Requires orthoses to walk due to hypotonia,					late	Early milestones mildly	Note		Gross motor delay
	+	+		+		+	+	+		+			+		+		+		+		+/-	ı		
12/13	Tremor and dysmetria	C/b tremor of hands	dysdiadochokinesis	C/b hemiparesis, tremor,	coordination by OT eval	Decreased fine motor	Poor handwriting	No additional info		No additional info	No additional info	cutting food; ↓coordination	Difficulty writing and		No additional info	zippers, and cutting tood	Difficulty with nandwriting, shoelaces, buttons,		Complicated by hypotonia	now age-appropriate	Unsteady/slow reach →	Reaches at 4mo, pincer grasp 9mo, utensils 2y	•	Fine motor delay
	+	ı		+		+	+	+		+	+		+		+		+		+		ı	I		
	+	Normal sp		+		+	I	I		+	+		-/+		++		+		I		I	1 st word	(first word,	Lang
11/13	Limited vocab	Normal speech development	expressive aphasia	Dysarthria,	-	Apraxia	Dysarthria	5-word vocab		3-word vocab	None		Dysarthria		Few words		3-word vocab				Age appropriate	Notes	first word, age of sentences)	Language delay
	+	+/-		+		+	+	+		+	+		•		+		+		I		ı		()	n
9/13 + 1 drop in IQ	Developmentally 3y behind	IQ 105 \rightarrow 76 in 6y		IQ in 50s	functionally mild	WISC-V IQ 48 but	Mild, 1-3 years below peers	Severe impairment		No additional info	Mild-moderate impairment	Slow	School acquisitions	years younger)	Severe intellectual disability (est 10		Full Scale IQ: 48	normal)	Full Scale IQ: 87(low-		No concerns	IQ > 70 to 75	(IQ or clinical estimate)	Intellectual disability

Supplementary Table 3: Proband phenotypes (developmental delay and intellectual disability) Normal milestones based on updated guidelines from CDC and American Association of Pediatrics (7). Any amount of delay was counted. C/b = complicated by.

P#

Behavioral/psychiatric disorders

Other neurological disorders

Abnormal brain MRI

Magnetic resonance imaging studies (MRIs) were read at the collaborator's institution. ADHD = attention-deficit/hyperactivity disorder, AED = antiepileptic drug, EEG = electroencephalogram, FLAIR = fluid attention inversion recovery sequence, PDD = pervasive developmental disorder.

		•		
+	Mildly low-set ears, anteverted nares, prominent forehead and chin, positional plagiocephaly	+	Torticollis, inguinal hernia requiring repair, mild hypospadias w/chordee	Pyloric stenosis at s/p pylorotomy, mild thoracolumbar kyphosis
+	Broad forehead with frontal bossing, long face,	+	Bilateral hydrocele	Leg pronation/abnormal hip alignment
	posteriorly rotated ears (L mildly low-set), deep-			requiring orthotics, asthma, constipation, joint
•	Broad forehead, deep-set eyes, bitemporal	+	Inward-turning feet requiring	GERD, constipation, small kidneys
	narrowing, space between upper incisors, thin upper lip		splinting	w/hydronephrosis, short stature (2 nd percentile)
+	DSPF, convex nasal ridge, overhanging nasal	+	Punctate corneal clouding, thin	Scoliosis
	tip, uplifted earlobes, thin upper lip, protuberant		diaphysis/underdeveloped	
	lower jaw, high palate, long toes		epiphyses of long bones,	
			calcaneovagus deformity, umbilical hernia s/p repair	
ı	Frontal bossing	+	Congenital hydrocephalus	Astigmatism, hyperopia, GERD
+	Dolichocephaly, mild frontal bossing, deep	ı	None noted	Mild myopia
			-	
	slanting PF and eyebrows, low-set/dysplastic		foramen ovale/atrial septal defect.	
	ears, long smooth philtrum with thin upper lip,			
	retrognathia, single palmar crease	ĺ		
+	Frontal bossing with asymmetry, DSPF,	+	Bilateral hip dysplasia requiring	Strabismus, GERD, gastritis, constipation with
	hypotelorism, ptosis, microretrognathia, high		cryptorchidism requiring surgery	encopresis, apneic episodes in infancy
•	High foot arches (16-20y), no surgery required	ı	None	Scoliosis, mild astigmatism, glasses
	Low-lying columella, thin upper lip	ı	None	Thoracolumbar scoliosis, history of feeding
+	Prominent forehead, low-set ears, DSPF, thin	·	None	Ketotic hypoglycemia 0-6y, headaches,
	upper lip, smooth philtrum; hammer toes, hvoerflexible hands/feet. pes cavus			constipation, bitocals, skin biopsy w/granular deposits and ↓ eccrine glands muscle
				atrophy/cramps, R hemiparesis
•	Pes cavus (acquired) s/p surgery	+	Ventricular septal defect	Myopia, constipation
+	Broad forehead, synophrys, DSPF, ptosis, low-	+	Patent foramen ovale, large left	Many nevi, hyperphagia
	set posteriorly rotated ears with simplified folding, full cheeks, smooth philtrum, thin upper		kidney with duplication of urinary system	
	lip, microdontia, macroglossia			
	8/13		9/13	
12/13 + + + + + + + + + + + + + + + + + + +			 Mildly low-set ears, anteverted nares, prominent forehead and chin, positional plagiocephaly Broad forehead with frontal bossing, long face, posteriorly rotated ears (L mildly low-set), deeplate, thin upper lip Broad forehead, deep-set eyes, bitemporal narrowing, space between upper linc, upper lip, upper lip, posteriorly rotated earlobes, thin upper lip, protuberant lower jaw, high palate, long toes Frontal bossing Frontal bossing with asymmetry, DSPF, hypotelorism, ptosis, microretrognathia, high palate, deep-set eyes, down-retrognathia, single palmar crease High foot arches (16-20y), no surgery required Low-lying columella, thin upper lip Pess cavus (acquired) s/p surgery Broad forehead, synophrys, DSPF, ptosis, low-set posteriorly rotated ears with simplified folding, full cheeks, smooth philtrum, thin upper lip, microdontia, macroglossia 	+ Mildly low-set ears, anteverted nares, prominent + repair, mild hypospadias w/chor + Broad forehead with frontal bassing, long face, posteriorly rotated ears (L mildly low-set), deep posteriorly rotated ears (L mildly low-set), deep part, mild hypospadias w/chor + Bilateral hydrocele - Broad forehead, deep-set eyes, bitemporal narrowing, space between upper lip. + Inward-turning feet requiring splinting - Broad forehead, deep-set eyes, bitemporal lower jaw, high palate, long loes + Punctate corneal clouding, thin diphysics of long bones, claraneovagus deformity, umbil hord cephalus + DSPF, convex nasal ridge, overhanging nasal + Punctate corneal clouding, thin diphysics of long bones, lower jaw, high palate, long loes - None noted - + Dolichocephaly, mild frontal bossing, deep - None noted - None noted + Pontial anomalies - None noted - None noted - Forntal bossing with asymmetry, DSPF, is surgery, hydronephrosis, patent forehead, low-set eaves, DSPF, thin upper lip. + Patent ductus arteriosus, patent forehead, low-set eas, DSPF, thin surgery, hydronephrosis, cow-synghors, SIGSFF, patens, high palate, long bys, SIGSFF, patens, low-synghors, SIGSFF, bits, low- + None

P#

MC

Dysmorphic features

Congenital anomaly


Other medical history

feature or multiple minor features to be classified as dysmorphic. MC = macrocephaly (+ = absolute, Rel = relative)(8). * Normal OFC at birth with progressive macrocephaly. DS = downslanting, PF = palpebral fissures. GERD = gastroesophageal reflux disease, s/p = status post.


$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	D1∆ = in-frame deletion in D1, D1 or D2 = (see Figure 2C). Macrocephalv was absolute	$D1\Delta$ = in-frame deletion in D1, D1 or D2 =								enotypes	band phe	ized pro			Sunnlementary Table 6: Summarized proband phenotypes
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	3/13	+	+	ı	,	ı	ı	+	ı	ı	ı	·	ı	-	Cardiac
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	4/13	+		1			+	ı			•	1	+	+	GU
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	8/13		+	+	+	•	+	ı	•	+	ı	+	+	+	GI
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	8/13	1	+	+		+	+	+	+	+	+	1	•	ı	Ophthal.
1 2 3 4 5 6 7 8 9 10 11 12 13 FS D1 Splice D1 D1 <thd1< th=""> <thd1< th=""> <thd1< th=""></thd1<></thd1<></thd1<>	9/13		+	+	+	+	+	ı	•	1	+	+	+	+	MSK
	11/13	+	+	+	+	•	+	+	+	+	Rel	Rel	+	+	Macrocephaly
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	8/13	+		+			+	+	+		+	1	+	+	Dysmorphic
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$						I defects	congenita	tures and	orphic feat	Dysm					
	11/13	+	•	+	+	+	+	+	+	+	+	N/A	+	•	Abnl MRI
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	4/13	+	+	+			•	ı				•	•	+	Tremor
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	3/13	1	+	1	+		•	ı		+		•	•	1	Epilepsy
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	11/13	+		+	+	+	+	+	+	+	+	1	+	+	Hypotonia
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	4/13	1	+	1	+			ı		+	•	1	+	ı	Anxiety
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	3/13	ı	+			1	+	ı				+/-	+	-	Autism
1 2 3 4 5 6 7 8 9 10 11 12 13 FS D1 Splice D1 D2 D2 D2 D2 D1 D1 F M M F M M F M M F D1 D1 D2 D2 D2 D1 D1 D2 D2 D1 D1 <th< td=""><td>4/13</td><td>•</td><td>+</td><td>ı</td><td>+</td><td>+</td><td>1</td><td>ı</td><td>•</td><td>1</td><td>ı</td><td>ı</td><td>+</td><td>-</td><td>ADHD</td></th<>	4/13	•	+	ı	+	+	1	ı	•	1	ı	ı	+	-	ADHD
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$						ders	atric disord	ø	leurologic	7					
1 2 3 4 5 6 7 8 9 10 11 12 13 M M FS D1 Splice D1			(↓IQ)	Mod					Mod						
1 2 3 4 5 6 7 8 9 10 11 12 13 M M FS D1 Splice D1 D1 D1A D1A D1A D1 D2 D2 D2 D2 D1 F M F M F M F M F D1 D1A D1 D2 D2 D2 D2 D1 D1 F M M F F M M F F M M F F M M F F M F F M F F M F F M F F M F F M F F M F F M F F M F F M F F M F F M F F M F F M	9/13	+	ı	Mild-	Mild	Mild	Sev	Sev	Mild-	ı	Sev	Sev	+	I	D
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	11/13	Mod	ı	Mild	Mild	Mod	Sev	Sev	Mild	+	Sev	Sev	Mild-	ı	Language
1 2 3 4 5 6 7 8 9 10 11 12 13 FS D1 Splice D1 D1 D1 D1 D1 D1 D2 D2 D1 M M F M M F F M M F D2 D2 D1 0-5 6-10 6-10 11-15 6-10 0-5 6-10 16-20 11-15 21-25 16-20 11-15 2 - - + + + - - ++ - <td>12/13</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>ı</td> <td>+</td> <td>+</td> <td>+</td> <td>Mod</td> <td>+/-</td> <td>Fine motor</td>	12/13	+	+	+	+	+	+	+	ı	+	+	+	Mod	+/-	Fine motor
1 2 3 4 5 6 7 8 9 10 11 12 13 FS D1 Splice D1 D1 D1 D1 D1 D1 D2 D2 D1 M M F M M F F M M F D1 D1 D1 D2 D2 D1 0-5 6-10 6-10 11-15 6-10 0-5 0-5 6-10 16-20 11-15 21-25 16-20 11-15 - - + + + - - ++ -	13/13	Mild	Mild/-	Mild	Mild	Mild	Mod	+	Mod	Mod	Sev	Mild	Mod	Mild/-	Gross motor
1 2 3 4 5 6 7 8 9 10 11 12 13 FS D1 Splice D1 D2 D2 D1 D1 M M F M M F F M M F D1 D1 D1 D1 D2 D2 D1 D1 D1 D1 D1 D1 D1 D1 D2 D2 D1							al delay	elopmenta	Deve						
1 2 3 4 5 6 7 8 9 10 11 12 13 FS D1 Splice D1 D1 D1 D1 D1 D1 D2 D2 D2 D1) M M F M M F F M M F D2 D2 D1 0-5 6-10 6-10 11-15 6-10 0-5 0-5 6-10 16-20 11-15 21-25 16-20 11-15		ı	ı	ı	++	I	1	+	+	+	ı		ı		ATPase fx
1 2 3 4 5 6 7 8 9 10 11 12 13 FS D1 Splice D1 D1 D1A D1 D1A D1 D2 D2 D2 D1 M M F M M F F F M M F F M F M F		11-15	16-20	21-25	11-15	16-20	6-10	0-5	0-5	6-10	11-15	6-10	6-10	0-5	Age
1 2 3 4 5 6 7 8 9 10 11 12 13 FS D1 Splice D1 D1 D1 D1 D1 D1 D2 D2 D2 D1	7/6	п	R	П	п	Μ	Μ	п	п	Ν	Μ	п	Μ	Μ	Sex (M/F)
		D	D2	D2	D2	D1	D1∆	Ŋ	D1∆	D1	D1	Splice	D1	FS	Mutation
	Total	13	12	1	10	9	œ	7	ი	വ	4	ω	Ν	-	Proband

Genitourinary (GU) abnormalities include hypospadias, cryptorchidism, hydrocele, and duplicated collecting system. Cardiac abnormalities include atrial and ventricular septal defects and patent ductus arteriosus. *Proband 4: EEG with epileptic activity but no clinical seizures. strabismus, and hyperopia/myopia. Gastrointestinal (GI) abnormalities include pyloric stenosis, reflux, constipation, and poor feeding. deformities, and hip or foot dysplasias, deformities, or misalignments. Ophthalmologic abnormalities include corneal clouding, astigmatism, moderate 35-55, and severe <35. Musculoskeletal (MSK) abnormalities included kyphosis, scoliosis, hammer toes, pes cavus, long bone (moderate) >2x normal, sev (severe) = never reached milestone. For ID, based on IQ score < 75 and/or clinical impression, with mild IQ 55-75,

SUPPLEMENTARY MATERIALS




Supplementary Figure 1: 3D structure of variants of Probands 6 (F267del) and 8 (I130del). A, B) Two views of a section of VCP, with the F267 and I301 residues highlighted in green, and ADP in purple. 3D models are based on electron microscopy of VCP ADP-bound hexamer (7BP9, viewed in Uniprot browser)(64). In B), the phenylalanine and isoleucine residues are shown in ghost form, interacting with a nearby alpha helix that helps form the "top" surface of the hexamer. The same section of VCP is shown from modeling of the C-D) F267del and E-F) I301del variants, as predicted by the software RaptorX (37, 38). The overall secondary structure is roughly maintained, with no striking displacements of the nearby alpha helices.



Supplementary Figure 2: Conservation of affected VCP residues.

NCBI BLAST was used to align VCP protein sequences from human (*Homo sapiens*) against five model organisms: chimpanzee (*Pan troglodytes*), zebrafish (*Danio rerio*), fruit fly (*Drosophila melanogaster*), and yeast (*Saccharomyces cerevisiae*). Conserved residues are shown by dots, and variant amino acids are shown at each position. Positions affected in our probands are highlighted along with 10 amino acids on either side. Notably, every residue affected is conserved in these organisms, and most are in highly conserved areas.



Supplementary Figure 3: ATPase activity compared to wildtype and MSP variants A) Immunoblots of lysates from U2OS cells expressing empty vector or expression plasmids with *VCP* variants and a C-terminal Myc tag using an anti-VCP antibody (top), anti-Myc antibody (middle) or anti-GAPDH as loading control (bottom). B) *In vitro* constructs using myc-tagged VCP were created using variants described in classic multisystem proteinopathy ("MSP variants") and with the novel variants described in this paper. These constructs were transfected into U2OS cells that contained endogenous VCP, and ATPase activity was measured from cell lysates using standard colorimetric assays as in Figure 2C. Activity was normalized to wildtype (100%). In general, MSP variants have up to 5x increased ATPase activity, while most novel variants (with the exceptions of R256G, S541Y, and F267del) had decreased activity.

PROBAND INFORMATION

Please contact corresponding author if you are interested in more detailed clinical information about our probands.

Proband 1

VCP variant: c.265del (p.R89Gfs*8)

Genetic Testing: Trio whole exome sequencing identified a *de novo* frameshift alteration in *VCP* (c.265del; p.Arg89GlyfsTer8) and no other reportable variants were identified.

Methods: Standard laboratory procedures were followed for whole exome trio analysis performed in a diagnostic laboratory. Briefly, Agilent SureSelectXT Clinical Research Exome kit was used to target known disease-associated exonic regions of the genome and sequenced with Illumina NovaSeq[™] 6000 System with 150 bp paired-end reads. Data were aligned with Illumina DRAGEN Bio-IT Platform software (hg19/NCBI build 37) and the emedgene software (Illumina) was used to filter and analyze variants.

Proband 2

VCP variant: c.685C>T (p.L229F)

Genetic Testing: Trio whole exome sequencing revealed two VUS; a *de novo* mutation in *VCP* (c.685C>T, p.L229F), and a maternally inherited mutation in *TRPC5* (c.2332T>C, p.S778P). Other testing included normal CMA in 2014 and a 23 CGG repeat on Fragile X testing. The proband was enrolled in the SPARK study for autism; no additional genetic variants were found.

Methods: DNA was isolated from the proband and his parent's blood samples or cheek swabs using standard methods and sent to GeneDx for trio whole exome sequencing. Analysis from GeneDx used their usual protocol: an Illumina system was used to obtain sequences which were then aligned to human genome build GRCh37/UCSC hg19 and analyzed using Xome Analyzer. Pathogenic variants were confirmed by capillary sequencing or other appropriate method, and variants in the proband were compared to parental samples. Re-analysis by GeneDx in 2019 did not change their classification or report any additional variants.

Proband 3

VCP variant: c.709-2A>G (splice variant)

Genetic Testing: Trio whole exome sequencing was performed, which found a VCP c.709-2A>G splice variant. She also had a normal chromosomal microarray.

Methods: DNA was isolated from the proband and her parent's blood samples or cheek swabs using standard methods and sent to GeneDx for trio whole exome sequencing. Analysis from GeneDx used their usual protocol, as for Proband 2. The variant found was reported as a de novo variant of uncertain significance.

Proband 4

VCP variant: c.753G>T (p.K251R)

Genetic Testing: A *de novo* VCP variant, c.753G>T (p.Lys251Arg), was identified by trio whole exome sequencing. Testing with normal results performed prior to exome sequencing included: Chromosomal microarray, *FMR1* sequencing, MLPA for Angelman/Prader Willi syndrome,

MLPA and sequencing for *ZEB2*, and a developmental disorders gene sequencing panel (DDG2P, contains 1641 genes, performed in 2017). No other genetic lesion was found.

Methods: Trio whole-exome analysis was performed at Telemark Hospital Trust. Nextera Rapid Capture Exome Enrichment Kit (Illumina) was used for sample preparation and a NextSeq 500 (Illumina) for 2x150 bp sequencing. Reads were mapped to the reference genome (GRCh37/hg19) by BWA (Burrows-Wheeler Aligner)(12). GATK (Genome Analysis Toolkit) was used for variant calling (13). Variants were annotated by Annovar (14) and filtered with Filtus (15).

Proband 5

VCP variant: c.766C>G (p.R256G)

Genetic Testing: Gene panel testing detected a *de novo* c.766C>G, p.R256G variant in *VCP*. Chromosomal microarray was normal.

Methods: Sequencing was performed at the Molecular Genetics Laboratory at Brest University Hospital. The panel was comprised of ~500 genes associated with intellectual disabilities. A parental pool strategy was used, and variant above was confirmed to have *de novo* segregation by Sanger sequencing.

Proband 6

VCP variant: c.801_803del (p.F267del)

Genetic Testing: Trio exome sequence detected a de novo variant in VCP, c.801_803del. She had chromosome analysis and array CGH with normal results. This variant was recently reported (Feb 2023) as a VUS in ClinVar (variation ID 1913089) (Last accessed March 2023).

Methods: Trio whole exome sequencing (WES) was performed at the Institute of Human Genetics, Helmholtz Center Munich. Exome-sequencing was performed with a SOLiD 5500XL machine (Life Technologies) after enrichment with the Agilent SureSelectXT Human All Exon 50Mb Kit (Agilent). The data were analyzed with LifeScope software (Applied Biosystems, Life Technologies). Trio-WES data were filtered for potentially pathogenic *de novo* variants absent in the general population (dbSNP138, 1000 Genomes Project, and gnomAD Browser) and rare biallelic variants with a minor allele frequency (MAF) <0.1% and no homozygous carriers in the aforementioned databases. The functional impact of identified putative pathogenic variants was predicted by the Combined Annotation Dependent Depletion (CADD) tool (5), the Rare Exome Variant Ensemble Learner (REVEL) scoring system (4), the Mendelian Clinically Applicable Pathogenicity (M-CAP) Score (16), the Sorting Intolerant from Tolerant (SIFT) program (17, 18), and the Polymorphism Phenotyping v.2 (PolyPhen-2) tool (19).

Proband 7

VCP variant: c.812G>A (p.G271D)

Genetic Testing: The VCP c.812G>A variant was found on trio exome sequencing. This was classified as a *de novo* variant of uncertain significance by the sequencing lab. She previously had a chromosome analysis, array CGH, and Prader-Willi syndrome methylation analysis that were normal. Reportedly, metabolic screening tests on her 2nd day of life that were also unremarkable.

Methods: Written informed consent for sequencing and research was obtained in accordance with the German gene diagnostics act and the declaration of Helsinki. Sequencing was performed at the laboratory of Charité Universitätsmedizin Berlin. Genomic DNA was extracted from whole blood samples and exome enrichment performed using the SureSelect Human All Exon Kit V6 (Agilent Technologies). Samples were sequenced on an Illumina NovaSeq6000 in 2x100bp paired-end mode. Reads were mapped to the human reference genome GRCh37/hg19 and variants filtered by minor allele frequency, mode of inheritance and predicted impact using the VarFish platform (20).

Proband 8

VCP variant: c.901_903del (p.I301del)

Genetic Testing: Trio whole exome sequencing was performed and a *de novo* variant in *VCP* [NM_007126.5:c.901_903del, p.(Ile301del)] was identified in the proband. No other notable variants were reported. Prior negative genetic workup included MLPA for the SNRPN locus, karyotyping, and array CGH.

Methods: Trio whole exome sequencing was performed at the D&R Institute for Human Genetics, Medical University of Graz. DNA was extracted using the QIASymphony DSP DNA Midi Kit on a QIASymphony SP instrument (QIAGEN, Hilden, Germany). Nextera DNA Flex Library Prep Kit was used for library preparation. Sequencing was performed on a NextSeg 550 (Illumina, San Diego, California, USA). Alignment to the human reference sequence (GRCh37/hg19 assembly) and variant calling were performed with the DRAGEN Germline Pipeline V.3.2.8 on Illumina BaseSpace (https://basespace.illumina.com/). Variant annotation and filtering was done via VarSeg[™] v 2.2.2 (Golden Helix, Inc., Montana, UCS, www.goldenhelix.com). For variant prioritization following human phenotype ontology (HPO) terms were used: HP:0001263 Global developmental delay, HP:0100716 Self-injurious behavior, HP:0000729 Autistic behavior, HP:0006970 Periventricular leukomalacia, HP:0025069 Concomitant strabismus, HP:0020045 Esodeviation, HP:0001252 Muscular hypotonia, HP:0002705 High, narrow palate, HP:0001385 Hip dysplasia, HP:0000028 Cryptorchidism, HP:0000256 Macrocephaly, HP:0002007 Frontal bossing, HP:0000494 Downslanted palpebral fissures, HP:0000601 Hypotelorism, HP:0005656 Positional foot deformity, HP:0000308 Microretrognathia, HP:0005949 Apneic episodes in infancy.

Proband 9

VCP variant: c.1084C>T (p.R362C)

Genetic Testing: Trio exome sequencing revealed a single reported finding, a c.10842C>T (p.R362C) *de novo* variant of uncertain significance in *VCP*. Mitochondrial DNA sequencing did not find any pathogenic variants. Unremarkable karyotype, subtelomeric FISH, oligo microarray, and Fragile-X repeat analysis. *SLC22A5* pathogenic variant discussed above.

Methods: Genomic DNA from the submitted proband was enriched for the complete coding regions and splice site junctions for most genes of the human genome using a proprietary capture system developed by GeneDx for next-generation sequencing with CNV calling (NGS-CNV). Data were aligned to reference sequences based on NCBI RefSeq transcripts and human genome build GRCh37/UCSC hg19 and analyzed to identify sequence variants and most deletions and duplications involving three or more coding exons.

Proband 10

VCP variant: c.1622C>A (p.S541Y)

Genetic Testing: GeneDx's Autism/ID Xpanded panel identified a c.1622C>A (p.S541Y) variant in *VCP*. No other variants were reported. Prior testing includes karyotype, SNP microarray, and Fragile-X analysis which were normal.

Methods: Genomic DNA from the proband and both parents was analyzed using nextgeneration sequencing with CNV calling. Analysis was targeted a phenotypic-driven gene list (GeneDX Autism/ID Xpanded panel). Data were aligned to reference sequences based on NCBI RefSeq transcripts and human genome build 10 GRCh37/UCSC hg19 and analyzed to identify sequence variants and most deletions and duplications involving three or more coding exons.

Proband 11

VCP variant: c.1874G>C (p.R625P)

Genetic Testing: Whole exome sequencing showed a heterozygous *de novo* variant in *VCP* (c.1874 G>C), classified as "variant, likely mutation." The following were normal: *ATM*, *CDKL5/STK9, DYT1, MeCP2, PEO1, POLG1,* partial CMT-axonal DNA testing, Friedreich ataxia, Fragile X, mtDNA point mutation and deletion panel, and chromosomal 15 PCR test.

Methods: Trio exome sequencing was performed at GeneDx on blood from the proband and parents using Agilent SureSelect XT2 All Exon V4 kit, the Illumina 2000 sequencing system (214X mean depth coverage), mapped to the human genome build UCSC hg19 reference.

Proband 12

VCP variant: c.2257C>T

Genetic Testing: Trio whole exome sequencing identified a paternally inherited variant of uncertain significance in *VCP*, c.2257C>T (p.R753W). It was reanalyzed as an adult which did not report any new variants or secondary findings. He also had an unremarkable chromosomal microarray.

Methods: Trio whole exome sequencing and re-analysis was performed at GeneDx, using their usual protocols.

Proband 13

VCP variant: c.892C>T (p.P298S)

Genetic Testing: Previous workup was normal and included CMA, sequencing of *SLC2A1* and *STXBP1*, and chromosome 15 methylation studies.

Methods: Not available for this proband.

REFERENCES

- Richards, S., Aziz, N., Bale, S., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*, 17(5): 405-424 (2015).
- 2. Abou Tayoun, A. N., Pesaran, T., DiStefano, M.T., et al. Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. *Hum Mutat*, 39(11): 1517-1524 (2018).
- 3. Pejaver, V., Byrne, A. B., Feng, B., et al. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for use of PP3/BP4 criteria. *Am J Hum Genet*, 2022.
- Ioannidis N. M., Rothstein, J. H., Pejaver V., et al. REVEL: An Ensemble Method for Predicting the Pathogeneicity of Rare Missense Variants. *Am J Hum Genet*, 99(4): 877-885 (2016).
- 5. Rentzsch, P., Schubach, M., Shendure, J., & Kircher, M. CADD-Splice—improving genome-wide variant effect prediction using deep learning-derived splice scores. *Genome Med*, 13: 31 (2021).
- Muller, J. M., Deinhardt, K., Rosewell, I., et al. Targeted deletion of p97 (VCP/CDC48) in mouse results in early embryonic lethality. *Biochem Biophys Res Commun*, 354(2):459-465 (2007).
- 7. Zubler, J. M., Wiggins, L. D., Macias, M. M., et al. Evidence-Informed Milestones for Developmental Surveillance Tools. *Pediatrics*, 149(3):e2021052138 (2022).
- 8. Lainhart, J. E., Bigler, E. D., Bocian, M., et al. Head circumference and height in autism: a study by the Collaborative Program of Excellence in Autism. *Am J Med Genet*, 140A: 2257-2274 (2006).
- 9. Zhu, K., Cai, Y., Si, X., et al. The phosphorylation and dephosphorylation switch of VCP/p97 regulates the architecture of centrosome and spindle. *Cell Death Differ*, 29(10):2070-2088 (2022).
- 10. Källberg, M., Wang, H., Wang, S., et al. Template-based protein structure modeling using the RaptorX web server. *Nature Protoc*, 7(8): 1511-1522 (2012).
- 11. Wang, S., Sun, S., Li Z., et al. Accurate De Novo Prediction of Protein Contact Map by Ultra-Deep Learning Model. *PLOS Comput Biol*, 13(1):e1005324 (2017).
- 12. Li, H., & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics*, 25(14):1754-60 (2009),
- 13. DePristo M. A., Banks, E., Poplin, R., et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nature Genetics*, 43(5):491-8 (2011).
- 14. Wang, K., Li, M., & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res*, 38(16):e164 (2010)
- Vigeland, M. D., Gjotterud, K. S., & Selmer, K. K. FILTUS: a desktop GUI for fast and efficient detection of disease-causing variants, including a novel autozygosity detector. *Bioinformatics*, 32(10):1592-4 (2016).
- 16. Jagadeesh, K., Wenger, A., Berger, M., et al. M-CAP eliminates a majority of variants with uncertain significance in clinical exomes at high sensitivity. *Nat Genetics*, 48(12):1581 (2016).
- 17. Sim, N. L., Kumar, P., Hu, J., et al. SIFT web server: predicting effects of amino acid substitutions of proteins. *Nucleic Acid Res*, 40:W452-W457 (2012).
- 18. Ng, P. C. and Henikoff, S. Predicting deleterious amino acid substitutions. *Genome Res*, 11:863-874 (2001).

- 19. Abzhubei, I. A., Schmidt, S., Peshkin, L., et al. A method and server for predicting damaging missense mutations. *Nat Methods*, 7(4):248-249 (2010).
- 20. Holtgrewe, M., Stolpe, O., Nieminen, M., et al. VarFish: comprehensive DNA variant analysis for diagnostics and research. *Nucleic Acids Res*, 48(W1):W162-160 (2020).